Clearbridge Health announced that the Labnovation Technologies Covid-19 antigen rapid test (ART) kit, which is imported by Clearbridge to be used in the Philippines, has been approved by the Food and Drug Administration (FDA) of the Philippines for self-testing.
The FDA of the Philippines approved two self-administered Covid-19 ART Test Kits, one from Labnovation and one from Abott Panbio. These kits can be used by individuals to detect SARS-CoV-2 antigen from nasal swabs of probable Covid-19 patients.
The group is currently the only importer and distributor of Labnovation’s Covid-19 ART test
kit in the Philippines as the group has submitted and obtained the relevant regulatory
approval for the ART Test Kit to be used in the country.
Jeremy Yee, executive director and CEO of Clearbridge says, "In the Philippines, daily cases hit record highs in January following the detection of local cases of the Omicron variant."
"With the approval of Labnovation’s Covid-19 ART Test Kit for self-testing in the Philippines, we believe that it can serve as an important tool for routine testing by the public, offering
some peace of mind at the same time. We aim to work with various channel partners and point-of-care networks (such as clinics and pharmacies) in the Philippines for Labnovation’s Covid-19 ART Test Kit to gain wider market outreach and accessibility,” adds Yee.
Shares in Clearbridge closed at 9.7 cents on Jan 26.
See also: Sembcorp issues $350 mil of guaranteed notes due 2036 at 3.65%
Photo: Bloomberg
